NEW YORK


,


May 23, 2022


/PRNewswire/ —

Weiss Law

is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Entasis Therapeutics Holdings Inc. (“Entasis” or the “Company”) (NASDAQ: ETTX) in connection with the proposed acquisition of the Company by Innoviva, Inc. (NASDAQ: INVA) via a tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive

$2.20

in cash for each share of Entasis common stock owned.  The transaction is valued at approximately

$113 million

.

If you own




Entasis




shares




and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/ettx





Or please contact:





Joshua Rubin, Esq.



Weiss Law

305 Broadway, 7

^th

Floor


New York

, NY  10007


(212) 682-3025



(888) 593-4771


[email protected]

Weiss Law is investigating whether (i) Entasis’s board of directors (“Board”) acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the

$2.20

per-share merger consideration adequately compensates Entasis’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed, including whether INVA, that already owns approximately 60% of outstanding Entasis common stock, improperly coerced the Board to enter into the merger agreement.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at


[email protected]

View original content to download multimedia:

https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-entasis-therapeutics-holdings-inc-301553265.html

SOURCE Weiss Law